MC3 점액표피양 암종세포에서 비타민 K2의 항암효과
(주)코리아스칼라
- 최초 등록일
- 2016.04.02
- 최종 저작일
- 2014.10
- 6페이지/
어도비 PDF
- 가격 4,000원
* 본 문서는 배포용으로 복사 및 편집이 불가합니다.
서지정보
ㆍ발행기관 : 대한구강악안면병리학회
ㆍ수록지정보 : 대한구강악안면병리학회지 / 38권 / 5호
ㆍ저자명 : 장분실, 오세준, 신지애, 조남표, 조성대
목차
Ⅰ. INTRODUCTION
Ⅱ. MATERIALS AND METHODS
1. Reagents and antibodies
2. Cell Culture and Chemical Treatment
3. Trypan blue exclusion assay
4. DAPI staining
5. Western blot analysis
6. Statistical Analysis
Ⅲ. RESULTS
1. In vitro growth inhibitory effect of VK2 on MC3mucoepidermoid carcinoma cells
2. Morphological detection of apoptosis of MC3cells treated with VK2
3. Effects of VK2 on apoptosis and Bcl-2 familymembers in MC3 cells
IV. DISCUSSION
V. REFERENCES
영어 초록
Background. Vitamin K (VK) is a fat-soluble vitamin and is known to have anticancer activity in various cancer cell lines. However, there is no report on the anticancer effect of VK2 in mucoepidermoid carcinoma cells. Methods. The effects of VK2 on anti-proliferative and apoptotic activity were recognized by the trypan blue exclusion assay, 4'-6-diamidino-2-phenylindole (DAPI) staining and Western blot analysis. Results. The results showed that VK2 decreased cell viability and induced apoptotic programmed cell death in MC3 cells evidenced by the cleavages of caspase3 and PARP. VK2 treatment clearly increased Bak and truncated Bid (t-Bid) compared with the control treatment whereas it did not alter other Bcl-2 family members. Conclusions. Overall, our results suggest that VK2 can be a good apoptotic inducer accompanied by the increase in Bak and Bid protein. VK2 may be a potent target of anticancer drug candidate for the treatment of oral cancer.
참고 자료
없음
